Sientra (SIENQ) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Cover [Abstract]
Entity Registrant Name	SIENTRA, INC.
Entity Central Index Key	0001551693
Document Type	10-Q
Document Period End Date	Mar. 31, 2022
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		62,639,966
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	SIEN
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36709
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5551000
Entity Address, Address Line One	420 South Fairview Avenue
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Santa Barbara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	805
Local Phone Number	562-3500
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 38,883	$ 51,772
Accounts receivable, net of allowances of $2,581 and $2,278 at March 31, 2022 and December 31, 2021, respectively	39,265	33,105
Inventories, net	54,224	52,914
Prepaid expenses and other current assets	2,561	2,979
Current assets of discontinued operations	4	4
Total current assets	134,937	140,774
Property and equipment, net	13,085	13,998
Goodwill	9,202	9,202
Other intangible assets, net	27,890	28,765
Other assets	6,752	7,165
Total assets	191,866	199,904
Current liabilities:
Current portion of long-term debt	5,189	2,237
Accounts payable	9,112	7,402
Accrued and other current liabilities	18,055	21,298
Customer deposits	35,301	35,182
Sales return liability	16,493	13,399
Current liabilities of discontinued operations	500	500
Total current liabilities	84,650	80,018
Long-term debt	65,565	62,434
Deferred and contingent consideration	5,858	5,872
Warranty reserve and other long-term liabilities	10,707	10,723
Total liabilities	166,780	159,047
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.01 par value – Authorized 10,000,000 shares; none issued or outstanding	0	0
Common stock, $0.01 par value - Authorized 200,000,000 shares; issued 62,552,927 and 62,242,090 and outstanding 62,480,200 and 62,169,363 shares at March 31, 2022 and December 31, 2021, respectively	625	622
Additional paid-in capital	664,106	661,839
Treasury stock, at cost (72,727 shares at March 31, 2022 and December 31, 2021)	(260)	(260)
Accumulated deficit	(639,385)	(621,344)
Total stockholders' equity	25,086	40,857
Total liabilities and stockholders’ equity	$ 191,866	$ 199,904

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Accounts receivable, allowances (in dollars)	$ 2,581	$ 2,278
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	62,552,927	62,242,090
Common stock, shares outstanding	62,480,200	62,169,363
Treasury stock, shares	72,727	72,727

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales	$ 21,398,000	$ 18,312,000
Cost of goods sold	8,553,000	8,159,000
Gross profit	12,845,000	10,153,000
Operating expenses:
Sales and marketing	15,588,000	11,819,000
Research and development	3,144,000	2,195,000
General and administrative	10,208,000	7,911,000
Total operating expenses	28,940,000	21,925,000
Loss from operations	(16,095,000)	(11,772,000)
Other income (expense), net:
Interest income	2,000	2,000
Interest expense	(1,897,000)	(2,004,000)
Change in fair value of derivative liability		(42,740,000)
Other income (expense), net	5,000	(97,000)
Total other income (expense), net	(1,890,000)	(44,839,000)
Loss from continuing operations before income taxes	(17,985,000)	(56,611,000)
Income tax expense	0	0
Loss from continuing operations	(17,985,000)	(56,611,000)
Income (loss) from discontinued operations, net of income taxes	(56,000)	1,921,000
Net loss	$ (18,041,000)	$ (54,690,000)
Basic and diluted net loss per share attributable to common stock holders
Continuing operations	$ (0.29)	$ (1.04)
Discontinued operations	0	0.03
Basic and diluted net loss per share	$ (0.29)	$ (1.01)
Weighted average outstanding common shares used for net income (loss) per share attributable to common stockholders:
Basic and diluted	62,334,073	54,321,146

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common stock	Treasury stock	Additional paid-in capital	Accumulated deficit
Balance, beginning of year at Dec. 31, 2020	$ (557)	$ 506	$ (260)	$ 558,059	$ (558,862)
Balance, beginning of year (in shares) at Dec. 31, 2020		50,712,151	72,727
Proceeds from follow-on offering, net of costs	39,226	$ 62		39,164
Proceeds from follow-on offering, net of costs (shares)		6,222,222
Stock-based compensation	3,163			3,163
Stock option exercises	51			51
Stock option exercises (in shares)		12,727
Employee stock purchase program (ESPP)	323	$ 1		322
Employee stock purchase program (ESPP) (in shares)		95,919
Vested restricted stock	758	$ 6		752
Vested restricted stock (in shares)		554,896
Shares withheld for tax obligations on vested RSUs	(1,215)	$ (1)		(1,214)
Shares withheld for tax obligations on vested RSUs, shares		82,830
Net loss	(54,690)				(54,690)
Balance, end of year at Mar. 31, 2021	(12,941)	$ 574	$ (260)	600,297	(613,552)
Balance, end of year (in shares) at Mar. 31, 2021		57,515,085	72,727
Balance, beginning of year at Dec. 31, 2021	40,857	$ 622	$ (260)	661,839	(621,344)
Balance, beginning of year (in shares) at Dec. 31, 2021		62,242,090	72,727
Stock-based compensation	2,196			2,196
Employee stock purchase program (ESPP)	329	$ 1		328
Employee stock purchase program (ESPP) (in shares)		139,574
Vested restricted stock		$ 3		(3)
Vested restricted stock (in shares)		265,331
Shares withheld for tax obligations on vested RSUs	(255)	$ (1)		(254)
Shares withheld for tax obligations on vested RSUs, shares		94,068
Net loss	(18,041)				(18,041)
Balance, end of year at Mar. 31, 2022	$ 25,086	$ 625	$ (260)	$ 664,106	$ (639,385)
Balance, end of year (in shares) at Mar. 31, 2022		62,552,927	72,727

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (18,041)	$ (54,690)
Income (loss) from discontinued operations, net of income taxes	(56)	1,921
Loss from continuing operations, net of income taxes	(17,985)	(56,611)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,744	1,036
Provision for doubtful accounts	315	269
Provision for warranties	291	200
Provision for inventory	(56)	(9)
Fair value adjustments to derivative liability		42,740
Fair value adjustments of other liabilities held at fair value	0	17
Amortization of debt discount and issuance costs	938	848
Stock-based compensation expense	2,196	3,163
Other non-cash adjustments	60	213
Changes in operating assets and liabilities:
Accounts receivable	(6,474)	(1,276)
Inventories	(1,253)	(2,397)
Prepaid expenses, other current assets and other assets	907	(298)
Accounts payable, accrueds, and other liabilities	(1,754)	(6,574)
Customer deposits	118	4,051
Sales return liability	3,094	1,823
Net cash flow from operating activities - continuing operations	(17,859)	(12,805)
Net cash flow from operating activities - discontinued operations	(56)	138
Net cash used in operating activities	(17,915)	(12,667)
Cash flows from investing activities:
Purchase of property and equipment	(246)	(1,321)
Net cash flow from investing activities - continuing operations	(246)	(1,321)
Net cash flow from investing activities - discontinued operations	0	0
Net cash provided by (used in) investing activities	(246)	(1,321)
Cash flows from financing activities:
Proceeds from issuance of common stock for employee stock-based plans	329	1,132
Net proceeds from issuance of common stock	0	39,226
Tax payments related to shares withheld for vested restricted stock units (RSUs)	(255)	(1,215)
Gross borrowings under the Term Loan	5,000	1,000
Gross borrowings under the Revolving Loan	2,774	0
Repayment of the Revolving Loan	(2,552)	0
Deferred financing costs	(25)	(750)
Net cash provided by financing activities	5,271	39,393
Net increase (decrease) in cash, cash equivalents and restricted cash	(12,890)	25,405
Cash, cash equivalents and restricted cash at:
Beginning of period	52,068	55,310
End of period	39,178	80,715
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	38,883	80,372
Restricted cash included in other assets	$ 295	$ 343
Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
End of period	$ 39,178	$ 80,715
Supplemental disclosure of cash flow information:
Interest paid	1,070	1,058
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment in accounts payable and accrued liabilities	30	400
Deferred follow-on offering costs in accounts payable and accrued liabilities	0	122
Deferred financing costs in accounts payable and accrued liabilities	$ 298	$ 50

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sientra, Inc. (“Sientra”, the “Company”, “we”, “our”, or “us”) in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial reporting. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022, or the Annual Report. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As a result of the miraDry Sale discussed in Note 2, the miraDry business met the criteria to be reported as discontinued operations. Therefore, the Company is reporting the historical results of miraDry, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein through the date of the Sale. Unless otherwise noted, the accompanying notes to the unaudited condensed consolidated financial statements have all been revised to reflect continuing operations only. As discussed in Note 11, following the Sale the Company has one operating segment in continuing operations named Plastic Surgery, formerly known as Breast Products. b. Liquidity Since the Company’s inception, it has incurred significant net operating losses and the Company anticipates that losses will continue in the near term. The Company expects its operating expenses will remain consistent with the current period and will need to generate significant net sales to achieve profitability. To date, the Company has funded operations primarily with proceeds from the sales of preferred stock, borrowings under term loans and the convertible note, sales of products, and the proceeds from the sale of common stock in public offerings. The Company continues to evaluate overall capital needs, and while the Company believes there are sufficient capital resources to continue as a going concern over the next twelve months, the Company may be required to raise additional debt or equity capital to fund ongoing operations. As of March 31, 2022, the Company had cash and cash equivalents of $ 38.9 million. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. Debt financing – recent developments Refer to Note 7 for a full description and updates to all of the Company’s long-term debt, revolving line of credit, and convertible note. c. Recent Accounting Pronouncements Recently Issued Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The amendment eliminates certain accounting models and simplifies the accounting for convertible instruments and enhances disclosures for convertible instruments and earnings per share. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023 including interim periods within those fiscal years and early adoption is permitted. The Company is currently evaluating the impact that adoption of the standard will have on the condensed consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848)-Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendment provides optional expedients and exceptions for contract modifications that replace a reference rate affected by reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022, and entities may elect to apply by Topic as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. The Company is currently evaluating the impact the election of the optional expedient will have on the condensed consolidated financial statements. d. Risks and Uncertainties As an aesthetics company, surgical procedures involving the Company’s breast products are susceptible to local and national government restrictions, such as social distancing, vaccination requirements, “shelter in place” orders and business closures. The inability or limited ability to perform such non-emergency procedures and patients electing to postpone elective aesthetics procedures due to the pandemic significantly harmed the Company’s revenues since the second quarter of 2020 and continued to harm the Company’s revenues during the three months ended March 31, 2022. While many states have lifted certain restrictions on non-emergency procedures and procedural volume rates for non-emergency procedures have been recovering, the Company will likely continue to experience future harm to its revenues while existing or new restrictions remain in place. It is not possible to accurately predict the length or severity of the COVID-19 pandemic or the impact on the Company’s business, including the timing for a broad and sustained ability to perform non-emergency procedures involving the Company’s products. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. Further, the spread of COVID-19 has caused the Company to modify workforce practices, and the Company may take further actions determined to be in the best interests of the Company’s employees or as required by governments. The continued spread of COVID-19, or another infectious disease, could also result in delays or disruptions in the Company’s supply chain or adversely affect the Company’s manufacturing facilities and personnel. Further, trade and/or national security protection policies may be adjusted as a result of the COVID-19 pandemic, such as actions by governments that limit, restrict or prevent the movement of certain goods into a country and/or region, and current U.S./China trade relations may be further exacerbated by the pandemic. The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets and goodwill, and sales returns liability required could be impacted by the pandemic. While the full impact of COVID-19 is unknown at this time, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. These estimates may change as new events occur and additional information is obtained. e. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation, including those related to discontinued operations following the sale of the miraDry business.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2022
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	2. Discontinued Operations On June 10, 2021, the Company completed the sale of its miraDry business (the “Sale”) to miraDry Acquisition Company, Inc., a Delaware corporation (“Buyer”), an entity affiliated with 1315 Capital II, LP, as a result of the Company’s strategic decision to focus investment on its core Plastic Surgery segment. The Sale was made pursuant to the terms and conditions of the Asset Purchase Agreement (the “Purchase Agreement”), dated May 11, 2021, among the Company and certain of its subsidiaries, Buyer, and, solely for purposes of Section 8.14 of the Purchase Agreement, 1315 Capital II, LP. The aggregate purchase price was $ 10.0 million, which after certain adjustments for agreed upon changes in the estimated net asset value amount of purchased assets and assumed liabilities resulted in net cash proceeds of $ 11.3 million to the Company on the date of close. In October 2021, the Company finalized the transaction and paid $ 3.2 million to the Buyer in accordance with the agreed upon post close changes in the net asset value and recognized a loss on sale of $ 2.5 million. In accordance with the Purchase Agreement, assumed liabilities did not include product liabilities, environmental, and employee claims arising prior to the closing date. The Purchase Agreement also included customary representations and warranties, as well as certain covenants, including, among other things, that: (i) the Company will abide by certain non-solicitation, exclusivity, and non-competition covenants, and (ii) the Company would enter into a transition services agreement (“TSA”) to provide certain transition services related to the business. Under the TSA, the Company provided certain post-closing services to the Buyer related to the miraDry business for a period of six months , including accounting, accounts receivable support, customer service, IT, regulatory, quality assurance, and clinical support. As consideration for these services, the Buyer reimbursed the Company for direct and certain indirect costs, as well as certain overhead or administrative expenses related to operating the business. The Company recognized $ 0.1 million of TSA fees and cost reimbursements in operating expenses from continuing operations in the condensed consolidated statement of operations for the quarter ended March 31, 2022. As of March 31, 2022 , the Company has received $ 0.3 million relating to the TSA services and has recorded a receivable of $ 0.1 million within other current assets in the condensed consolidated balance sheets. In connection with the accounts receivable support under the TSA, the Company received $ 2.3 million in customer payments and remitted $ 2.3 million to the Buyer during the period from June 10, 2021 through March 31, 2022. As of March 31, 2022, the Company does not have a payable to the Buyer on the condensed consolidated balance sheets. Additionally, the Company and the Buyer entered into a sublease agreement whereby the Buyer subleased the miraDry office space in Santa Clara, CA. The sublease term was for an initial period of six months, with subsequent option periods for up to a total of twenty four months. Following the initial period, the Buyer exercised an additional period of six months. During quarter ended March 31, 2022, the Company recognized $ 0.2 million of sublease income in general and administrative expenses in the condensed consolidated statements of operations. The Sale met the discontinued operations criteria given that the business is a component and represented a strategic shift. The following table presents the aggregate carrying amounts of major classes of assets and liabilities of discontinued operations (in thousands): March 31, December 31, 2022 2021 Assets of discontinued operations: Prepaid expenses and other current assets $ 4 $ 4 Current assets of discontinued operations 4 4 Total assets of discontinued operations $ 4 $ 4 Liabilities of discontinued operations: Accounts payable $ 6 $ 6 Accrued and other current liabilities 494 494 Total liabilities of discontinued operations $ 500 $ 500 The results of operations for the miraDry business were included in income (loss) from discontinued operations on the accompanying condensed consolidated statements of operations. The following table provides information regarding the results of discontinued operations (in thousands): Three Months Ended March 31, 2022 2021 Net sales $ — $ 4,924 Cost of goods sold — 2,776 Gross profit — 2,148 Operating expenses 56 196 Income (loss) from operations of discontinued operations ( 56 ) 1,952 Other income (expense), net — ( 31 ) Income (loss) from discontinued operations before income taxes ( 56 ) 1,921 Total income (loss) from discontinued operations before income taxes ( 56 ) 1,921 Income tax expense (benefit) — — Income (loss) from discontinued operations, net of income taxes $ ( 56 ) $ 1,921 The results of the miraDry business, including the results of operations, cashflows, and related assets and liabilities are reported as discontinued operations for all periods presented herein.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	3. Revenue The Company generates revenue primarily through the sale and delivery of promised goods or services to customers. Sales prices are documented in the executed sales contract, purchase order or order acknowledgement prior to the transfer of control to the customer. Typical payment terms are 30 days. Revenue contracts may include multiple products or services, each of which is considered a separate performance obligation. Performance obligations typically include the delivery of promised products, such as breast implants, tissue expanders, and BIOCORNEUM, along with service-type warranties. Other deliverables are sometimes promised but are ancillary and insignificant in the context of the contract as a whole. Revenue is allocated to each performance obligation based on its relative standalone selling price. The Company determines standalone selling prices based on observable prices for all performance obligations with the exception of the service-type warranty under the Platinum20 Limited Warranty Program, or Platinum20, which is based on the expected cost plus margin approach. Inputs into the expected cost plus margin approach include historical incidence rates, estimated replacement costs, estimated financial assistance payouts and an estimated margin. The liability for unsatisfied performance obligations under the service warranty as of March 31, 2022 were as follows: Three Months Ended March 31, 2022 Balance as of December 31, 2021 $ 3,237 Additions and adjustments 555 Revenue recognized ( 176 ) Balance as of March 31, 2022 $ 3,616 Revenue for service warranties are recognized ratably over the term of the agreements. Specifically for Platinum20, the performance obligation is satisfied at the time that the benefits are provided and are expected to be satisfied over the following 3 to 24 month period for financial assistance and 20 years for product replacement. For delivery of promised products, control transfers and revenue is recognized upon shipment, unless the contractual arrangement requires transfer of control when products reach their destination, for which revenue is recognized once the product arrives at its destination. A portion of the Company’s revenue is generated from the sale of consigned inventory of breast implants and tissue expanders maintained at doctor, hospital, and clinic locations. For these products, revenue is recognized at the time the Company is notified by the customer that the product has been used, not when the consigned products are delivered to the customer’s location. Sales Return Liability With the exception of the Company’s BIOCORNEUM scar management products, the Company allows for the return of products from customers within six months after the original sale, which is accounted for as variable consideration. A sales return liability is established based on estimated returns using relevant historical experience taking into consideration recent gross sales and notifications of pending returns, as adjusted for changes in recent industry events and trends. The estimated sales returns are recorded as a reduction of revenue and as a sales return liability in the same period revenue is recognized. Actual sales returns in any future period are inherently uncertain and thus may differ from the estimates. If actual sales returns differ significantly from the estimates, an adjustment to revenue in the current or subsequent period would be recorded. The following table provides a rollforward of the sales return liability (in thousands): Three Months Ended March 31, 2022 2021 Beginning balance $ 13,399 $ 9,192 Addition to reserve for sales activity 41,870 36,386 Actual returns ( 37,030 ) ( 33,700 ) Change in estimate of sales returns ( 1,746 ) ( 858 ) Ending balance $ 16,493 $ 11,020

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Financial Instruments Owned At Fair Value [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, customer deposits and sales return liability are reasonable estimates of their fair value because of the short maturity of these items. The fair value of the contingent consideration is discussed in Note 5. The fair value of the debt is based on the amount of future cash flows associated with the instrument discounted using the Company’s market rate. As of March 31, 2022 , the carrying value of the long-term debt was not materially different from the fair value. As of March 31, 2022, the carrying value and fair value of the convertible note were as follows (in thousands): March 31, December 31, 2022 2021 Carrying value $ 48,268 $ 47,477 Fair value $ 43,110 $ 42,029

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	5. Balance Sheet Components a. Inventories Inventories, net consist of the following (in thousands): March 31, December 31, 2022 2021 Raw materials $ 1,743 $ 2,109 Work in progress 4,690 4,796 Finished goods 43,022 41,982 Finished goods - right of return 4,769 4,027 $ 54,224 $ 52,914 b. Property and Equipment Property and equipment, net consist of the following (in thousands): March 31, December 31, 2022 2021 Leasehold improvements $ 3,464 $ 2,734 Manufacturing equipment and tooling 9,577 9,922 Computer equipment 1,661 1,672 Software 6,344 6,379 Furniture and fixtures 1,179 1,542 22,225 22,249 Less accumulated depreciation ( 9,140 ) ( 8,251 ) $ 13,085 $ 13,998 Depreciation expense for the three months ended March 31, 2022 and 2021 was $ 0.8 million and $ 0.7 million, respectively. c. Goodwill and Other Intangible Assets, net Following the sale of the miraDry business, the Company has one reporting unit, Plastic Surgery, formerly known as Breast Products. The Company evaluates goodwill for impairment at least annually on October 1 st and whenever circumstances suggest that goodwill may be impaired. The carrying amount of goodwill as of March 31, 2022 and December 31, 2021 were as follows (in thousands): Plastic Surgery Balances as of December 31, 2021 Goodwill 23,480 Accumulated impairment losses ( 14,278 ) Goodwill, net $ 9,202 Balances as of March 31, 2022 Goodwill 23,480 Accumulated impairment losses ( 14,278 ) Goodwill, net $ 9,202 The components of the Company’s other intangible assets consist of the following (in thousands): Average Amortization March 31, 2022 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ ( 4,291 ) $ 649 Trade names - finite life 12 800 ( 406 ) 394 Manufacturing know-how 19 8,240 ( 1,858 ) 6,382 Developed technology 8 20,661 ( 646 ) 20,015 Total definite-lived intangible assets $ 34,641 $ ( 7,201 ) $ 27,440 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Average Amortization December 31, 2021 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ ( 4,224 ) $ 716 Trade names - finite life 12 800 ( 389 ) 411 Manufacturing know-how 19 8,240 ( 1,652 ) 6,588 Developed technology 8 20,600 - 20,600 Total definite-lived intangible assets $ 34,580 $ ( 6,265 ) $ 28,315 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Amortization expense for the three months ended March 31, 2022 and 2021 were $ 0.9 million and $ 0.3 million, respectively. The following table summarizes the future estimated amortization expense relating to the Company's definite-lived intangible assets as of March 31, 2022 (in thousands): Amortization Period Expense 2022 $ 3,374 2023 3,594 2024 3,449 2025 3,306 2026 3,133 Thereafter 10,584 $ 27,440 d. Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following (in thousands): March 31, December 31, 2022 2021 Payroll and related expenses $ 3,189 $ 5,188 Accrued severance 474 248 Accrued commissions 3,020 4,329 Accrued manufacturing 30 121 Deferred and contingent consideration, current portion 2,567 2,431 Audit, consulting and legal fees 131 185 Accrued sal es and marketing expenses 189 159 Lease liabilities 1,727 1,666 Other 6,728 6,971 $ 18,055 $ 21,298 e. Accrued warranties The following table provides a rollforward of the accrued assurance-type warranties (in thousands): Three Months Ended March 31, 2022 2021 Balance as of January 1 $ 2,505 $ 1,934 Warranty costs incurred during the period ( 158 ) ( 31 ) Changes in accrual related to warranties issued during the period 267 195 Changes in accrual related to pre-existing warranties 24 5 Balance as of March 31 $ 2,638 $ 2,103 As of March 31, 2022 and 2021, both balances are included in “Warranty reserve and other long-term liabilities”. f. Liabilities measured at fair value Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Contingent consideration The contingent consideration balance consists of milestone payments related to the acquisition of AuraGen and future royalty payments related to the acquisition of BIOCORNEUM. 100 %. Any subsequent changes to the fair value of contingent consideration will be recorded as an adjustment to the carrying value of the assets acquired. 21.0 %. Level 3. The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 and indicate the level of the fair value hierarchy utilized to determine such fair value (in thousands): Fair Value Measurements as of March 31, 2022 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 3,039 $ 3,039 $ — $ — $ 3,039 $ 3,039 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 3,114 $ 3,114 $ — $ — $ 3,114 $ 3,114 The following table provides a rollforward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): Contingent consideration liability Balance, December 31, 2021 $ 3,114 Change in fair value ( 75 ) Balance, March 31, 2022 $ 3,039 The liability for the current portion of contingent consideration is included in “Accrued and other current liabilities” and the long-term portion is included in “Deferred and contingent consideration” in the condensed consolidated balance sheets.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	6. Leases Components of lease expense were as follows: Three Months Ended March 31, Lease Cost Classification 2022 2021 Operating lease cost Operating expenses $ 414 $ 428 Operating lease cost Inventory 114 100 Sublease income Operating expenses ( 233 ) — Total operating lease cost $ 295 $ 528 Finance lease cost Amortization of right-of-use assets Operating expenses 3 10 Amortization of right-of-use assets Inventory 12 12 Interest on lease liabilities Other income (expense), net 1 2 Total finance lease cost $ 16 $ 24 Total lease cost $ 311 $ 552 Short-term lease expense for the three months ended March 31, 2022 and 2021 was not material. Supplemental cash flow information related to operating and finance leases for the three months ended March 31, 2022 was as follows (in thousands): 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 407 $ 418 Operating cash outflows from finance leases 13 24 Supplemental balance sheet information related to operating and finance leases was as follows (in thousands, except lease term and discount rate): March 31, December 31, 2022 2021 Reported as: Other assets Operating lease right-of-use assets $ 6,102 $ 6,488 Finance lease right-of-use assets 63 77 Total right-of use assets $ 6,165 $ 6,565 Accrued and other current liabilities Operating lease liabilities $ 1,655 $ 1,595 Fina nce lease liabilities 72 71 Warranty reserve and other long-term liabilities Operating lease liabilities 5,129 5,576 Finance lease liabilities 17 28 Total lease liabilities $ 6,873 $ 7,270 Weighted average remaining lease term (years) Operating leases 4 4 Finance leases 1 2 Weighted average discount rate Operating leases 8.19 % 8.16 % Finance leases 6.90 % 6.90 % As of March 31, 2022, maturities of the Company’s operating and finance lease liabilities are as follows (in thousands): Period Operating leases Finance leases Total 2022 $ 1,665 $ 50 $ 1,715 2023 2,267 38 2,305 2024 1,816 4 1,820 2025 896 — 896 2026 851 — 851 2027 582 — 582 Total lease payments $ 8,077 $ 92 $ 8,169 Less imputed interest 1,293 3 1,296 Total lease liabilities $ 6,784 $ 89 $ 6,873

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	7. Debt On March 30, 2022 (the “Effective Date”), the Company entered into a Third Amendment (the “Third Amendment”) to the Term Loan Agreement, with certain of the Company’s wholly owned subsidiaries, the lenders party thereto and MidCap, in order to provide the Company an additional tranche of funding and allow the Company to draw the fourth tranche. The Third Amendment provided that the fourth tranche of $ 5,000,000 was to be drawn on March 31, 2022. Additionally, the Third Amendment provides the Company with a sixth tranche pursuant to which the Company may draw $ 9,000,000 any time after January 1, 2023 until March 31, 2023. The Third Amendment also eliminated the minimum unrestricted cash requirement and reset the minimum Net Revenue (as defined therein) requirements based on the Company’s 12-month trailing Net Revenue. Finally, the Third Amendment increased the prepayment fee by 0.5 % until following the third anniversary of the Effective Date, at which point no prepayment fee shall apply. As of March 31, 2022 , there was $ 21.0 million of outstanding principal and $ 0.3 million of an exit fee payable related to the term loans, reduced by unamortized debt issuance costs of $ 0.8 million included in "Current portion of long-term debt" and $ 0.5 million included in “Long-term debt” on the condensed consolidated balance sheets. Also on March 30, 2022, the Company entered into a Sixth Amendment (the “Sixth Amendment”) to the Revolving Loan Agreement, with certain of the Company’s wholly owned subsidiaries, the lenders party thereto and MidCap. The Sixth Amendment modified the Net Revenue (as defined therein) requirement in a manner consistent with the modification under the Restated Term Loan Agreement. In addition, the Sixth Amendment made other conforming changes to the Restated Term Loan Agreement. As of March 31, 2022, there were $ 2.5 million outstanding under the Revolving Loan. As of March 31, 2022, the unamortized debt issuance costs related to the revolving loan was approximately $ 41,000 and was included in “Other assets” on the condensed consolidated balance sheets. The amortization of debt issuance costs on the term loan and the revolving loan for the three months ended March 31, 2022 and 2021 were $ 0.1 million and $ 0.2 million, respectively, and was included in interest expense in the condensed consolidated statements of operations. The Credit Agreements include customary affirmative and restrictive covenants and representations and warranties, including a financial covenant for minimum revenues, a financial covenant for minimum cash requirements, a covenant against the occurrence of a “change in control,” financial reporting obligations, and certain limitations on indebtedness, liens, investments, distributions, collateral, mergers or acquisitions, taxes, and deposit accounts. Upon the occurrence of an event of default, a default interest rate of an additional 5.0 % may be applied to any outstanding principal balances, and MidCap may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreements. The Company’s obligations under the Credit Agreements are secured by a security interest in substantially all of the Company’s assets. Convertible Note As of March 31, 2022, the unamortized debt discount and issuance costs were $ 11.7 million and included in “Long-term debt” on the condensed consolidated balance sheet. The Company will amortize the debt discount and debt issuance costs to interest expense under the effective interest method over the term of the Note, at a resulting effective interest rate of approximately 12 %. For the three months ended March 31, 2022 and 2021, the amortization of the convertible debt discount and issuance costs were $ 0.8 million and $ 0.7 million, respectively. Both were included in interest expense in the condensed consolidated statements of operations. Future Principal Payments of Debt The future schedule of principal payments for all outstanding debt as of March 31, 2022 was as follows (in thousands): Fiscal Year 2022 $ 2,460 2023 14,000 2024 7,000 2025 60,000 Total $ 83,460

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stockholders' Equity	8. Stockholders’ Equity a. Authorized Stock The Company’s Amended and Restated Certificate of Incorporation authorizes the Company to issue 210,000,000 shares of common and preferred stock, consisting of 200,000,000 shares of common stock with $ 0.01 par value and 10,000,000 shares of preferred stock with $ 0.01 par value. As of March 31, 2022 and December 31, 2021 , the Company had no preferred stock issued or outstanding. b. Stock Option Plans As of March 31, 2022, a total of 2,290,949 shares of the Company’s common stock were available for issuance under the 2014 Plan. As of March 31, 2022, inducement grants for 2,342,893 shares of common stock have been awarded, and 272,313 shares of common stock were available for future issuance under the Inducement Plan. Options under the 2007 Plan and the 2014 Plan may be granted for periods of up to ten years as determined by the Company’s board of directors, provided, however, that (i) the exercise price of an ISO shall not be less than 100 % of the estimated fair value of the shares on the date of grant, and (ii) the exercise price of an ISO granted to a more than 10 % shareholder shall not be less than 110 % of the estimated fair value of the shares on the date of grant. An NSO has no such exercise price limitations. NSOs under the Inducement Plan may be granted for periods of up to ten years as determined by the board of directors, provided, the exercise price will not be less than 100 % of the estimated fair value of the shares on the date of grant. Options generally vest with 25 % of the grant vesting on the first anniversary and the balance vesting monthly on a straight-lined basis over the requisite service period of three additional years for the award. Additionally, options have been granted to certain key executives that vest upon achievement of performance conditions based on performance targets as defined by the board of directors, which have included net sales targets and defined corporate objectives over the performance period with possible payout ranging from 0 % to 100 % of the target award. Compensation expense is recognized on a straight-lined basis over the vesting term of one year based upon the probable performance target that will be met. The vesting provisions of individual options may vary but provide for vesting of at least 25 % per year. The following summarizes all option activity under the 2007 Plan, 2014 Plan and Inducement Plan: Weighted Weighted average remaining Option exercise contractual Shares price term (year) Balances at December 31, 2021 1,703,963 $ 4.75 5.41 Granted 150,000 — Forfeited ( 8,598 ) 13.49 Balances at March 31, 2022 1,845,365 $ 4.32 5.56 For stock-based awards the Company recognizes compensation expense based on the grant date fair value using the Black-Scholes option valuation model. Stock-based compensation expense related to stock options for both the three months ended March 31, 2022 and 2021 were $ 0.1 million. As of March 31, 2022, unrecognized compensation costs related to stock options was $ 1.7 million. c. Restricted Stock Units The Company has issued restricted stock unit awards, or RSUs, under the 2014 Plan and the Inducement Plan. The RSUs issued to employees generally vest on a straight-line basis annually over a 3 -year requisite service period. RSUs issued to non-employees generally vest either monthly or annually over the service term. Activity related to RSUs is set forth below: Weighted Number grant date of shares fair value Balances at December 31, 2021 2,799,552 $ 8.11 Granted 2,683,961 2.54 Vested ( 265,331 ) 5.17 Forfeited ( 18,831 ) 0.31 Balances at March 31, 2022 5,199,351 $ 5.41 Stock-based compensation expense for RSUs for the three months ended March 31, 2022 and 2021 was $ 1.9 million and $ 2.9 million, respectively. As of March 31, 2022, there was $ 13.5 million of total unrecognized compensation costs related to non-vested RSU awards. The cost is expected to be recognized over a weighted average period of approximately 2.32 years. d. Employee Stock Purchase Plan The Company’s board of directors adopted the 2014 Employee Stock Purchase Plan, or ESPP, in July 2014, and the stockholders approved the ESPP in October 2014. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15 % of their eligible compensation, subject to any plan limitations. The ESPP provides for offering periods not to exceed 27 months, and each offering period will include purchase periods, which will be the approximately six-month period commencing with one exercise date and ending with the next exercise date. Employees are able to purchase shares at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the purchase date. A total of 255,500 shares of common stock were initially reserved for issuance under the ESPP, subject to certain annual increases. During the three months ended March 31, 2022, employees purchased 139,574 shares of common stock at a weighted average price of $ 2.36 per share. As of March 31, 2022, the number of shares of common stock available for future issuance was 1,735,734 . The Company estimated the fair value of employee stock purchase rights using the Black-Scholes model. Stock-based compensation expense related to the ESPP was $ 0.1 million for both the three months ended March 31, 2022 and 2021. e. Significant Modifications During the three months ended March 31, 2022 and 2021 , there were no material modifications of equity awards.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Loss Per Share Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding, to the extent they are dilutive. Potential dilutive shares consist of shares that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Dilutive net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive. Three Months Ended March 31, 2022 2021 Loss from continuing operations $ ( 17,985 ) $ ( 56,611 ) Income (loss) from discontinued operations, net of income taxes ( 56 ) 1,921 Net loss $ ( 18,041 ) $ ( 54,690 ) Weighted average common shares outstanding, basic and diluted 62,334,073 54,321,146 Basic and diluted net loss per share attributable to common stockholders Continuing operations $ ( 0.29 ) $ ( 1.04 ) Discontinued operations ( 0.00 ) 0.03 Basic and diluted net loss per share $ ( 0.29 ) $ ( 1.01 ) The Company excluded the following potentially dilutive securities, outstanding for the three months ended March 31, 2022 and 2021, from the computation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2022 and 2021 because they had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the periods. Three Months Ended March 31, 2022 2021 Stock issuable upon conversion of convertible note 14,634,146 14,634,146 Stock options to purchase common stock 30,033 1,687,409 Unvested RSUs 2,668,069 1,902,195 17,332,248 18,223,750

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company operates in several tax jurisdictions and is subject to taxes in each jurisdiction in which it conducts business. To date, the Company has incurred cumulative net losses and maintains a full valuation allowance on its net deferred tax assets due to the uncertainty surrounding realization of such assets. The Company had no tax expense for both the three months ended March 31, 2022 and 2021 .

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	11. Segment Information Following the sale of the miraDry business on June 10, 2021, the Company has one reportable segment named Plastic Surgery, formally known as Breast Products. The Plastic Surgery segment focuses on sales of silicone gel breast implants, tissue expanders, scar management products, and the fat grafting system under the brands Sientra Smooth, Sientra Teardrop, AlloX2, Dermaspan, Softspan, BIOCORNEUM, and AuraGen. The net sales, net operating loss and net assets for the Plastic Surgery segment are presented in the condensed consolidated statement of operations and condensed consolidated balance sheets as continuing operations.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies The Company is subject to claims and assessment from time to time in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Product Liability Litigation On October 7, 2019, a lawsuit was filed in the Superior Court of the State of California against the Company and Silimed Industria de Implantes Ltda. (the Company’s former contract manufacturer). The lawsuit alleges that the Company’s textured breast implants caused certain of the plaintiffs to develop a condition known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”), and that the Company is liable to the plaintiffs based on claims for strict liability (failure to warn), strict liability (defective manufacture), negligence and loss of consortium. On January 21, 2020, the Company filed a demurrer to the plaintiff’s complaint, which demurrer the Court granted in a tentative ruling dated March 9, 2021 with leave to replead. The Plaintiffs filed an amended complaint on April 6, 2021 and the Company filed a demurrer to that complaint on May 6, 2021. On October 25, 2021, the Court issued a ruling granting the Company’s demurrer in-part and denying it in-part, and gave plaintiffs twenty days to file an amendment complaint. A second amended complaint was filed on November 19, 2021. On December 3, 2021 the Company filed a renewed motion for demurrer as to all plaintiffs based on the recent FDA labelling updates on BIA-ALCL warnings. On January 5, 2022 the Company filed a demurrer to the second amended complaint as to plaintiff Craft and otherwise filed an Answer denying the remaining plaintiff's claims and asserting affirmative defenses. The Company's renewed demurrer as to all plaintiffs, and demurrer as to Craft is scheduled for oral argument on September 20, 2022. The Company intends to vigorously defend itself in this lawsuit. Given the nature of this case, the Company is unable to estimate the reasonably possible loss or range of loss, if any, arising from this matter. On September 23, 2020, a lawsuit was filed in the Eastern District of Tennessee against the Company. The lawsuit alleges that the Company’s textured breast implants caused certain of the plaintiffs to develop a condition known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”), and that the Company is liable to the plaintiffs based on claims for negligence, strict liability (manufacturing defects), strict liability (failure to warn), breach of express and implied warranties, and punitive damages. The Company filed a motion to dismiss the complaint on December 7, 2020. On February 28, 2022 the Court granted the Company’s motion, and dismissed the plaintiff’s complaint with prejudice. On March 28, 2022, the plaintiff filed a motion for reconsideration of the Court’s order. The Company opposed that motion on April 11, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sientra, Inc. (“Sientra”, the “Company”, “we”, “our”, or “us”) in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial reporting. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022, or the Annual Report. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As a result of the miraDry Sale discussed in Note 2, the miraDry business met the criteria to be reported as discontinued operations. Therefore, the Company is reporting the historical results of miraDry, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein through the date of the Sale. Unless otherwise noted, the accompanying notes to the unaudited condensed consolidated financial statements have all been revised to reflect continuing operations only. As discussed in Note 11, following the Sale the Company has one operating segment in continuing operations named Plastic Surgery, formerly known as Breast Products.
Liquidity	b. Liquidity Since the Company’s inception, it has incurred significant net operating losses and the Company anticipates that losses will continue in the near term. The Company expects its operating expenses will remain consistent with the current period and will need to generate significant net sales to achieve profitability. To date, the Company has funded operations primarily with proceeds from the sales of preferred stock, borrowings under term loans and the convertible note, sales of products, and the proceeds from the sale of common stock in public offerings. The Company continues to evaluate overall capital needs, and while the Company believes there are sufficient capital resources to continue as a going concern over the next twelve months, the Company may be required to raise additional debt or equity capital to fund ongoing operations. As of March 31, 2022, the Company had cash and cash equivalents of $ 38.9 million. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. Debt financing – recent developments Refer to Note 7 for a full description and updates to all of the Company’s long-term debt, revolving line of credit, and convertible note.
Recent Accounting Pronouncements	c. Recent Accounting Pronouncements Recently Issued Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The amendment eliminates certain accounting models and simplifies the accounting for convertible instruments and enhances disclosures for convertible instruments and earnings per share. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023 including interim periods within those fiscal years and early adoption is permitted. The Company is currently evaluating the impact that adoption of the standard will have on the condensed consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848)-Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendment provides optional expedients and exceptions for contract modifications that replace a reference rate affected by reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022, and entities may elect to apply by Topic as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. The Company is currently evaluating the impact the election of the optional expedient will have on the condensed consolidated financial statements.
Risks and Uncertainties	d. Risks and Uncertainties As an aesthetics company, surgical procedures involving the Company’s breast products are susceptible to local and national government restrictions, such as social distancing, vaccination requirements, “shelter in place” orders and business closures. The inability or limited ability to perform such non-emergency procedures and patients electing to postpone elective aesthetics procedures due to the pandemic significantly harmed the Company’s revenues since the second quarter of 2020 and continued to harm the Company’s revenues during the three months ended March 31, 2022. While many states have lifted certain restrictions on non-emergency procedures and procedural volume rates for non-emergency procedures have been recovering, the Company will likely continue to experience future harm to its revenues while existing or new restrictions remain in place. It is not possible to accurately predict the length or severity of the COVID-19 pandemic or the impact on the Company’s business, including the timing for a broad and sustained ability to perform non-emergency procedures involving the Company’s products. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. Further, the spread of COVID-19 has caused the Company to modify workforce practices, and the Company may take further actions determined to be in the best interests of the Company’s employees or as required by governments. The continued spread of COVID-19, or another infectious disease, could also result in delays or disruptions in the Company’s supply chain or adversely affect the Company’s manufacturing facilities and personnel. Further, trade and/or national security protection policies may be adjusted as a result of the COVID-19 pandemic, such as actions by governments that limit, restrict or prevent the movement of certain goods into a country and/or region, and current U.S./China trade relations may be further exacerbated by the pandemic. The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets and goodwill, and sales returns liability required could be impacted by the pandemic. While the full impact of COVID-19 is unknown at this time, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. These estimates may change as new events occur and additional information is obtained.
Reclassifications	e. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation, including those related to discontinued operations following the sale of the miraDry business.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations And Disposal Groups [Abstract]
Schedule of Disposal Groups Including Discontinued Operations Balance Sheet and Income Statement	The following table presents the aggregate carrying amounts of major classes of assets and liabilities of discontinued operations (in thousands): March 31, December 31, 2022 2021 Assets of discontinued operations: Prepaid expenses and other current assets $ 4 $ 4 Current assets of discontinued operations 4 4 Total assets of discontinued operations $ 4 $ 4 Liabilities of discontinued operations: Accounts payable $ 6 $ 6 Accrued and other current liabilities 494 494 Total liabilities of discontinued operations $ 500 $ 500 The following table provides information regarding the results of discontinued operations (in thousands): Three Months Ended March 31, 2022 2021 Net sales $ — $ 4,924 Cost of goods sold — 2,776 Gross profit — 2,148 Operating expenses 56 196 Income (loss) from operations of discontinued operations ( 56 ) 1,952 Other income (expense), net — ( 31 ) Income (loss) from discontinued operations before income taxes ( 56 ) 1,921 Total income (loss) from discontinued operations before income taxes ( 56 ) 1,921 Income tax expense (benefit) — — Income (loss) from discontinued operations, net of income taxes $ ( 56 ) $ 1,921

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Schedule of Rollforward of Sales Return Liability	The following table provides a rollforward of the sales return liability (in thousands): Three Months Ended March 31, 2022 2021 Beginning balance $ 13,399 $ 9,192 Addition to reserve for sales activity 41,870 36,386 Actual returns ( 37,030 ) ( 33,700 ) Change in estimate of sales returns ( 1,746 ) ( 858 ) Ending balance $ 16,493 $ 11,020
Schedule of Liability for Unsatisfied Performance Obligations Under Service Warranty	The liability for unsatisfied performance obligations under the service warranty as of March 31, 2022 were as follows: Three Months Ended March 31, 2022 Balance as of December 31, 2021 $ 3,237 Additions and adjustments 555 Revenue recognized ( 176 ) Balance as of March 31, 2022 $ 3,616

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Financial Instruments Owned At Fair Value [Abstract]
Schedule of Carrying Value and Fair Value of Convertible Note	As of March 31, 2022, the carrying value and fair value of the convertible note were as follows (in thousands): March 31, December 31, 2022 2021 Carrying value $ 48,268 $ 47,477 Fair value $ 43,110 $ 42,029

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of inventories, net	Inventories, net consist of the following (in thousands): March 31, December 31, 2022 2021 Raw materials $ 1,743 $ 2,109 Work in progress 4,690 4,796 Finished goods 43,022 41,982 Finished goods - right of return 4,769 4,027 $ 54,224 $ 52,914
Schedule of property and equipment, net	Property and equipment, net consist of the following (in thousands): March 31, December 31, 2022 2021 Leasehold improvements $ 3,464 $ 2,734 Manufacturing equipment and tooling 9,577 9,922 Computer equipment 1,661 1,672 Software 6,344 6,379 Furniture and fixtures 1,179 1,542 22,225 22,249 Less accumulated depreciation ( 9,140 ) ( 8,251 ) $ 13,085 $ 13,998
Schedule of Carrying Amount of Goodwill	The carrying amount of goodwill as of March 31, 2022 and December 31, 2021 were as follows (in thousands): Plastic Surgery Balances as of December 31, 2021 Goodwill 23,480 Accumulated impairment losses ( 14,278 ) Goodwill, net $ 9,202 Balances as of March 31, 2022 Goodwill 23,480 Accumulated impairment losses ( 14,278 ) Goodwill, net $ 9,202
Schedule of Other Intangible assets	The components of the Company’s other intangible assets consist of the following (in thousands): Average Amortization March 31, 2022 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ ( 4,291 ) $ 649 Trade names - finite life 12 800 ( 406 ) 394 Manufacturing know-how 19 8,240 ( 1,858 ) 6,382 Developed technology 8 20,661 ( 646 ) 20,015 Total definite-lived intangible assets $ 34,641 $ ( 7,201 ) $ 27,440 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Average Amortization December 31, 2021 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ ( 4,224 ) $ 716 Trade names - finite life 12 800 ( 389 ) 411 Manufacturing know-how 19 8,240 ( 1,652 ) 6,588 Developed technology 8 20,600 - 20,600 Total definite-lived intangible assets $ 34,580 $ ( 6,265 ) $ 28,315 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450
Schedule of Future Estimated Amortization Expense	The following table summarizes the future estimated amortization expense relating to the Company's definite-lived intangible assets as of March 31, 2022 (in thousands): Amortization Period Expense 2022 $ 3,374 2023 3,594 2024 3,449 2025 3,306 2026 3,133 Thereafter 10,584 $ 27,440
Schedule of accrued and other current liabilities	Accrued and other current liabilities consist of the following (in thousands): March 31, December 31, 2022 2021 Payroll and related expenses $ 3,189 $ 5,188 Accrued severance 474 248 Accrued commissions 3,020 4,329 Accrued manufacturing 30 121 Deferred and contingent consideration, current portion 2,567 2,431 Audit, consulting and legal fees 131 185 Accrued sal es and marketing expenses 189 159 Lease liabilities 1,727 1,666 Other 6,728 6,971 $ 18,055 $ 21,298
Schedule of rollforward of the accrued assurance-type warrantie	The following table provides a rollforward of the accrued assurance-type warranties (in thousands): Three Months Ended March 31, 2022 2021 Balance as of January 1 $ 2,505 $ 1,934 Warranty costs incurred during the period ( 158 ) ( 31 ) Changes in accrual related to warranties issued during the period 267 195 Changes in accrual related to pre-existing warranties 24 5 Balance as of March 31 $ 2,638 $ 2,103
Schedule of Company's Liabilities that are Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 and indicate the level of the fair value hierarchy utilized to determine such fair value (in thousands): Fair Value Measurements as of March 31, 2022 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 3,039 $ 3,039 $ — $ — $ 3,039 $ 3,039 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 3,114 $ 3,114 $ — $ — $ 3,114 $ 3,114
Schedule of Aggregate Fair Values of Company's Liabilities for which Fair Value is Determined by Level 3 Inputs	The following table provides a rollforward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): Contingent consideration liability Balance, December 31, 2021 $ 3,114 Change in fair value ( 75 ) Balance, March 31, 2022 $ 3,039

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Components of Lease Expense	Components of lease expense were as follows: Three Months Ended March 31, Lease Cost Classification 2022 2021 Operating lease cost Operating expenses $ 414 $ 428 Operating lease cost Inventory 114 100 Sublease income Operating expenses ( 233 ) — Total operating lease cost $ 295 $ 528 Finance lease cost Amortization of right-of-use assets Operating expenses 3 10 Amortization of right-of-use assets Inventory 12 12 Interest on lease liabilities Other income (expense), net 1 2 Total finance lease cost $ 16 $ 24 Total lease cost $ 311 $ 552
Supplemental Cash Flow Information Related to Operating and Finance Leases	Supplemental cash flow information related to operating and finance leases for the three months ended March 31, 2022 was as follows (in thousands): 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 407 $ 418 Operating cash outflows from finance leases 13 24
Supplemental Balance Sheet Information Related to Operating and Finance Leases	Supplemental balance sheet information related to operating and finance leases was as follows (in thousands, except lease term and discount rate): March 31, December 31, 2022 2021 Reported as: Other assets Operating lease right-of-use assets $ 6,102 $ 6,488 Finance lease right-of-use assets 63 77 Total right-of use assets $ 6,165 $ 6,565 Accrued and other current liabilities Operating lease liabilities $ 1,655 $ 1,595 Fina nce lease liabilities 72 71 Warranty reserve and other long-term liabilities Operating lease liabilities 5,129 5,576 Finance lease liabilities 17 28 Total lease liabilities $ 6,873 $ 7,270 Weighted average remaining lease term (years) Operating leases 4 4 Finance leases 1 2 Weighted average discount rate Operating leases 8.19 % 8.16 % Finance leases 6.90 % 6.90 %
Maturities of Operating and Finance Lease Liabilities	As of March 31, 2022, maturities of the Company’s operating and finance lease liabilities are as follows (in thousands): Period Operating leases Finance leases Total 2022 $ 1,665 $ 50 $ 1,715 2023 2,267 38 2,305 2024 1,816 4 1,820 2025 896 — 896 2026 851 — 851 2027 582 — 582 Total lease payments $ 8,077 $ 92 $ 8,169 Less imputed interest 1,293 3 1,296 Total lease liabilities $ 6,784 $ 89 $ 6,873

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Future Principal Payments for Outstanding Debt	The future schedule of principal payments for all outstanding debt as of March 31, 2022 was as follows (in thousands): Fiscal Year 2022 $ 2,460 2023 14,000 2024 7,000 2025 60,000 Total $ 83,460

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of option activity	The following summarizes all option activity under the 2007 Plan, 2014 Plan and Inducement Plan: Weighted Weighted average remaining Option exercise contractual Shares price term (year) Balances at December 31, 2021 1,703,963 $ 4.75 5.41 Granted 150,000 — Forfeited ( 8,598 ) 13.49 Balances at March 31, 2022 1,845,365 $ 4.32 5.56
Summary of RSUs activity	Activity related to RSUs is set forth below: Weighted Number grant date of shares fair value Balances at December 31, 2021 2,799,552 $ 8.11 Granted 2,683,961 2.54 Vested ( 265,331 ) 5.17 Forfeited ( 18,831 ) 0.31 Balances at March 31, 2022 5,199,351 $ 5.41

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of net loss per share, basic and diluted	Three Months Ended March 31, 2022 2021 Loss from continuing operations $ ( 17,985 ) $ ( 56,611 ) Income (loss) from discontinued operations, net of income taxes ( 56 ) 1,921 Net loss $ ( 18,041 ) $ ( 54,690 ) Weighted average common shares outstanding, basic and diluted 62,334,073 54,321,146 Basic and diluted net loss per share attributable to common stockholders Continuing operations $ ( 0.29 ) $ ( 1.04 ) Discontinued operations ( 0.00 ) 0.03 Basic and diluted net loss per share $ ( 0.29 ) $ ( 1.01 )
Schedule of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders	The Company excluded the following potentially dilutive securities, outstanding for the three months ended March 31, 2022 and 2021, from the computation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2022 and 2021 because they had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the periods. Three Months Ended March 31, 2022 2021 Stock issuable upon conversion of convertible note 14,634,146 14,634,146 Stock options to purchase common stock 30,033 1,687,409 Unvested RSUs 2,668,069 1,902,195 17,332,248 18,223,750

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 38,883	$ 51,772	$ 80,372

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Receivable	$ 39,265	$ 33,105
Accounts payable	9,112	$ 7,402
Sublease Income	200
Transition Services Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
TSA fees and cost reimbursements in operating expenses from continuing operations	100
Payments relating to the TSA services	300
Receivable relating to TSA services	2,300
Remittance relating to TSA services	$ 2,300
Sublease Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sublease term initial period	6 months
Other Current Assets | Transition Services Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Receivable	$ 100
miraDry
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from sale of assets	10,000
Net upfront cash proceeds	11,300
Loss on sale of businesses	(2,500)
Payment for post close changes in net asset value	$ 3,200

Discontinued Operations - Summa

Discontinued Operations - Summary of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets of discontinued operations:
Prepaid expenses and other current assets	$ 4	$ 4,000
Current assets of discontinued operations	4	4
Total assets of discontinued operations	4	4
Liabilities of discontinued operations:
Accounts payable	6	6
Accrued and other current liabilities	494	494
Total liabilities of discontinued operations	$ 500	$ 500

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Information Regarding the Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Discontinued Operation Income Loss From Discontinued Operation Disclosures [Abstract]
Net sales		$ 4,924
Cost of goods sold		2,776
Gross profit		2,148
Operating expenses	$ 56	196
Income (loss) from operations of discontinued operations	(56)	1,952
Other income (expense), net		(31)
Income (loss) from discontinued operations before income taxes	(56)	1,921
Total income (loss) from discontinued operations before income taxes	(56)	1,921
Income (loss) from discontinued operations, net of income taxes	$ (56)	$ 1,921

Revenue (Details 1)

Revenue (Details 1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01	Mar. 31, 2022
Product Replacement
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	20 years
Breast Products and Consumable miraDry products
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	30 days
Maximum | Financial Assistance
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	24 months
Minimum | Financial Assistance
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	3 months

Revenue (Details)

Revenue (Details)	3 Months Ended
	Mar. 31, 2022
Change In Contract With Customer Liability [Abstract]
Period for sales return	6 months

Revenue - Schedule of Liability

Revenue - Schedule of Liability for Unsatisfied Performance Obligations Under Service Warranty and Deliverables Under Certain Marketing Programs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Change In Contract With Customer Liability [Abstract]
Balance as of December 31, 2021	$ 3,237
Additions and adjustments	555
Revenue recognized	(176)
Balance as of March 31, 2022	$ 3,616

Revenue - Schedule of Rollforwa

Revenue - Schedule of Rollforward of Sales Return Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue Recognition [Abstract]
Beginning balance	$ 13,399	$ 9,192
Addition to reserve for sales activity	41,870	36,386
Actual returns	(37,030)	(33,700)
Change in estimate of sales returns	(1,746)	(858)
Ending balance	$ 16,493	$ 11,020

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of Convertible Note (Details) - Convertible Note - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Carrying Value	$ 48,268	$ 47,477
Fair Value	$ 43,110	$ 42,029

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 1,743	$ 2,109
Work in progress	4,690	4,796
Finished goods	43,022	41,982
Finished goods - right of return	4,769	4,027
Inventory, net	$ 54,224	$ 52,914

Balance Sheet Components (PPE)

Balance Sheet Components (PPE) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 22,225		$ 22,249
Less accumulated depreciation	(9,140)		(8,251)
Property and equipment, net	13,085		13,998
Depreciation expense	800	$ 700
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,464		2,734
Manufacturing equipment and toolings
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,577		9,922
Computer equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,661		1,672
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,344		6,379
Furniture and fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,179		$ 1,542

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Goodwill and intangible assets
Goodwill, net	$ 9,202	$ 9,202
Plastic Surgery
Goodwill and intangible assets
Goodwill	23,480	23,480
Accumulated impairment losses	(14,278)	(14,278)
Goodwill, net	$ 9,202	$ 9,202

Balance Sheet Components - Comp

Balance Sheet Components - Components of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 34,641	$ 34,580
Accumulated Amortization	(7,201)	(6,265)
Intangible Assets, net	27,440	28,315
Indefinite-lived intangible assets	$ 450	$ 450
Customer relationships
Finite Lived Intangible Assets [Line Items]
Average Amortization Period	10 years	10 years
Gross Carrying Amount	$ 4,940	$ 4,940
Accumulated Amortization	(4,291)	(4,224)
Intangible Assets, net	$ 649	$ 716
Trade name
Finite Lived Intangible Assets [Line Items]
Average Amortization Period	12 years	12 years
Gross Carrying Amount	$ 800	$ 800
Accumulated Amortization	(406)	(389)
Intangible Assets, net	394	411
Indefinite-lived intangible assets	$ 450	$ 450
Manufacturing know-how
Finite Lived Intangible Assets [Line Items]
Average Amortization Period	19 years	19 years
Gross Carrying Amount	$ 8,240	$ 8,240
Accumulated Amortization	(1,858)	(1,652)
Intangible Assets, net	$ 6,382	$ 6,588
Developed Technology
Finite Lived Intangible Assets [Line Items]
Average Amortization Period	8 years	8 years
Gross Carrying Amount	$ 20,661	$ 20,600
Accumulated Amortization	(646)	0
Intangible Assets, net	$ 20,015	$ 20,600

Balance Sheet Components (Goodw

Balance Sheet Components (Goodwill and Other Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other intangible assets
Amortization expense	$ 0.9	$ 0.3

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Future Estimated Amortization Expense (Details) $ in Thousands	Mar. 31, 2022USD ($)
Estimated amortization expense
2022	$ 3,374
2023	3,594
2024	3,449
2025	3,306
2026	3,133
Thereafter	10,584
Total amortization	$ 27,440

Balance Sheet Components (Accru

Balance Sheet Components (Accrued liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued and other current liabilities
Payroll and related expenses	$ 3,189	$ 5,188
Accrued severance	474	248
Accrued commissions	3,020	4,329
Accrued manufacturing	30	121
Deferred and contingent consideration, current portion	2,567	2,431
Audit, consulting and legal fees	131	185
Accrued sales and marketing expenses	189	159
Lease liabilities	1,727	1,666
Other	6,728	6,971
Total	$ 18,055	$ 21,298
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of rollforward of the accrued assurance-type warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning Balance	$ 2,505	$ 1,934
Warranty costs incurred during the period	(158)	(31)
Changes in accrual related to warranties issued during the period	267	195
Changes in accrual related to pre-existing warranties	24	5
Ending Balance	$ 2,638	$ 2,103
Monte-Carlo Simulation Model | Measurement Input, Volatility Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assumption for Fair Value of Interests Continued to be Held by Transferor Servicing Assets or Liabilities Volatility Rate	100.00%

Balance Sheet Components (Liabi

Balance Sheet Components (Liabilities measured at fair value) (Details)	3 Months Ended
	Mar. 31, 2022
Measurement Input, Discount Rate | BIOCORNEUM | Future Royalty Payments
Fair Value Measurements
Fair value measurement discount rate	21.00%

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Company's Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Measurements
Fair value liability	$ 3,039
Contingent Consideration Liability
Fair Value Measurements
Fair value liability	3,039	$ 3,114
Derivative Liability
Fair Value Measurements
Fair value liability		3,114
Level 3
Fair Value Measurements
Fair value liability	3,039
Level 3 | Contingent Consideration Liability
Fair Value Measurements
Fair value liability	$ 3,039	3,114
Level 3 | Derivative Liability
Fair Value Measurements
Fair value liability		$ 3,114

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Aggregate Fair Values of Company's Liabilities for which Fair Value is Determined by Level 3 Inputs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value Measurements
Balance at beginning of the period	$ 3,114
Level 3 | Contingent Consideration Liability | Fair Value, Recurring
Fair Value Measurements
Change in fair value	(75)
Balance at the end of the period	$ 3,039

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Lease Description [Line Items]
Total operating lease cost	$ 295	$ 528
Sublease income	(200)
Finance lease cost
Total finance lease cost	16	24
Total lease cost	311	552
Inventory
Lessee Lease Description [Line Items]
Total operating lease cost	114	100
Finance lease cost
Amortization of right-of-use assets	12	12
Operating Expenses
Lessee Lease Description [Line Items]
Total operating lease cost	414	428
Sublease income	(233)
Finance lease cost
Amortization of right-of-use assets	3	10
Other Income (Expense), Net
Finance lease cost
Interest on lease liabilities	$ 1	$ 2

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$ 407	$ 418
Operating cash outflows from finance leases	$ 13	$ 24

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Operating and Finance Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets And Liabilities Lessee [Abstract]
Operating lease right-of-use assets	$ 6,102	$ 6,488
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance lease right-of-use assets	$ 63	$ 77
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Total right-of use assets	$ 6,165	$ 6,565
Operating lease liabilities	$ 1,655	$ 1,595
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Finance lease liabilities	$ 72	$ 71
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Operating lease liabilities	$ 5,129	$ 5,576
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember
Finance lease liabilities	$ 17	$ 28
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember
Total lease liabilities	$ 6,873	$ 7,270
Weighted average remaining lease term (years)
Operating leases	4 years	4 years
Finance leases	1 year	2 years
Weighted average discount rate
Operating leases	8.19%	8.16%
Finance leases	6.90%	6.90%

Leases - Maturities of Operatin

Leases - Maturities of Operating and Finance Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating Lease Liabilities, Payments Due [Abstract]
Operating leases, 2022	$ 1,665
Operating leases, 2023	2,267
Operating leases, 2024	1,816
Operating leases, 2025	896
Operating leases, 2026	851
Operating leases, 2027	582
Total operating lease payments	8,077
Less imputed interest, Operating leases	1,293
Total operating lease liabilities	6,784
Finance Lease Liabilities, Payments, Due [Abstract]
Finance leases, 2022	50
Finance leases, 2023	38
Finance leases, 2024	4
Total finance lease payments	92
Less imputed interest, Finance leases	3
Total finance lease liabilities	89
Lessee Lease Liability Payments Due [Abstract]
2022	1,715
2023	2,305
2024	1,820
2025	896
2026	851
2027	582
Total lease payments	8,169
Less imputed interest	1,296
Total lease liabilities	$ 6,873	$ 7,270

Debt (Details)

Debt (Details) - USD ($)	Jul. 25, 2017	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2021
Line Of Credit Facility [Line Items]
Additional interest (as a percent)	5.00%
Common stock, shares issued		62,552,927			62,242,090
Amortization of debt issuance costs and discounts		$ 938,000		$ 848,000
Increase in percentage of payment fee		0.50%
Tranche 6
Line Of Credit Facility [Line Items]
Debt Instrument principal amount		$ 9,000,000
Restated Term Loan Agreement
Line Of Credit Facility [Line Items]
Loan amount outstanding		21,000
Unamortized debt issuance costs			$ 500,000
Unamortized debt discount and issuance costs		800,000
Exit fee payable		300,000
Revolving Loan
Line Of Credit Facility [Line Items]
Loan amount outstanding		2,500,000
Revolving Loan | Other Assets
Line Of Credit Facility [Line Items]
Unamortized debt issuance costs			$ 41,000
Term Loan and Revolving Loan
Line Of Credit Facility [Line Items]
Amortization of debt issuance costs		100,000		200,000
Term Loan and Revolving Loan | Tranche 4
Line Of Credit Facility [Line Items]
Debt Instrument principal amount				5,000,000
Deerfield Facility Agreement | Convertible Note
Line Of Credit Facility [Line Items]
Amortization of debt issuance costs				$ 700,000
Unamortized debt discount and issuance costs		$ 11,700,000
Debt instrument interest rate			12.00%
Amortization of debt issuance costs and discounts			$ 800,000

Debt (Schedule of Future Princi

Debt (Schedule of Future Principal Payments of Outstanding Debt) (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
2022	$ 2,460
2023	14,000
2024	7,000
2025	60,000
Total	$ 83,460

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Stock other disclosures
Common and preferred stock, shares authorized	210,000,000			210,000,000
Common stock, shares authorized	200,000,000	200,000,000		200,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000		10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares issued	0	0		0
Preferred stock, shares outstanding	0	0

Stockholders' Equity (Options)

Stockholders' Equity (Options) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Stock options
Number of options
Balance at the beginning of period (in shares)	1,703,963
Options granted (in shares)	150,000
Options forfeited (in shares)	(8,598)
Balance at the end of the period (in shares)	1,845,365	1,703,963
Weighted average exercise price
Balance at the beginning of period (in dollars per share)	$ 4.75
Options exercised (in dollars per share)	0
Options forfeited (in dollars per share)	13.49
Balance at the end of period (in dollars per share)	$ 4.32	$ 4.75
Additional information
Weighted average remaining contractual term	5 years 6 months 21 days	5 years 4 months 28 days
Stock-based compensation expense	$ 0.1
Unrecognized compensation costs (in dollars)			$ 1.7
2014 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	2,290,949
Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	272,313
Number of shares awarded	2,342,893
Grant period of stock awards	10 years
Number of additional years of requisite service period	3 years
Vesting period	1 year
Inducement Plan | On the first anniversary
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage	25.00%
Inducement Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant	100.00%
Percentage of possible payouts of the target award	0.00%
Inducement Plan | Minimum | Individual options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage	25.00%
Inducement Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of possible payouts of the target award	100.00%
2007 Plan and 2014 Plan | Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant period of stock awards	10 years
2007 Plan and 2014 Plan | Stock options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant	100.00%
Percentage of voting power owned by shareholder	10.00%
2007 Plan and 2014 Plan | Stock options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant	110.00%

Stockholders' Equity (Restricte

Stockholders' Equity (Restricted Stock) (Details) - Restricted stock units - 2014 Plan - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2020
Stockholders' Equity, other disclosures
Requisite service period, annually			3 years
Stock-based compensation expense	$ 1.9	$ 2.9
Unrecognized compensation costs (in dollars)	$ 13.5
Weighted average period over which unrecognized compensation costs are expected to be recognized	2 years 3 months 25 days
Number of shares
Balance at beginning of the period	2,799,552
Granted	2,683,961
Vested	(265,331)
Forfeited	(18,831)
Balance at end of the period	5,199,351
Weighted average grant date fair value
Balance at beginning of the period	$ 8.11
Granted	2.54
Vested	5.17
Forfeited	0.31
Balance at end of the period	$ 5.41

Stockholders' Equity (Stock Pur

Stockholders' Equity (Stock Purchase) (Details) - 2014 Employee Stock Purchase Plan - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Oct. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase period of offering	6 months
Rate of purchase price of stock on fair value (as a percent)	85.00%
Purchases under the award	139,574
Weighted Average purchase price	$ 2.36
Number of shares available for future grants	1,735,734
Stock-based compensation expense	$ 100,000	$ 100,000
Incremental compensation cost	$ 0	$ 0
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount rate on the value of shares through payroll deductions (as a percent)	15.00%
Expiration period of each offering	27 months
Number of shares reserved for future issuance			255,500

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Loss from continuing operations	$ (17,985)	$ (56,611)
Income (loss) from discontinued operations, net of income taxes	(56)	1,921
Net loss	$ (18,041)	$ (54,690)
Weighted Average Number of Shares Outstanding, Basic and Diluted	62,334,073	54,321,146
Earnings Per Share, Basic and Diluted [Abstract]
Continuing operations	$ (0.29)	$ (1.04)
Discontinued operations	0	0.03
Basic and diluted net loss per share	$ (0.29)	$ (1.01)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Potentially dilutive securities
Potentially dilutive securities	17,332,248	18,223,750
Stock issuable upon conversion of convertible note
Potentially dilutive securities
Potentially dilutive securities	14,634,146	14,634,146
Stock options to purchase common stock
Potentially dilutive securities
Potentially dilutive securities	30,033	1,687,409
Unvested RSUs
Potentially dilutive securities
Potentially dilutive securities	2,668,069	1,902,195

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Tax expense	$ 0	$ 0

Segment Information (Details)

Segment Information (Details)	3 Months Ended
	Mar. 31, 2022Segment
Segment Reporting [Abstract]
Number of reportable segments	1